Match!
Dean F. Bajorin
Memorial Sloan Kettering Cancer Center
CancerPathologyChemotherapyBladder cancerMedicine
504Publications
65H-index
17.1kCitations
What is this?
Publications 513
Newest
#1Gopa Iyer (Cornell University)H-Index: 26
#2Christopher Michael Tully (Cornell University)H-Index: 3
Last. Ashley Marie Regazzi (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 11
view all 13 authors...
Abstract Introduction To determine drug delivery/toxicity, and pathological/surgical outcomes of muscle-invasive bladder cancer (MIBC) patients receiving neoadjuvant gemcitabine-cisplatin (GC) plus radical cystectomy-pelvic lymph node dissection (RC-PLND). Patients and Methods Chemotherapy and surgical/pathologic outcomes were retrospectively analyzed with 5-year survival follow-up at a referral center. Post-neoadjuvant chemotherapy (NAC) pathologic endpoints included complete response (pT0N0), ...
Source
#1Shawn Dason (OSU: Ohio State University)
#2Nathan Colin Wong (MSK: Memorial Sloan Kettering Cancer Center)
Last. Jonathan E. Rosenberg (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 46
view all 15 authors...
PURPOSE: To determine the diagnostic performance of (18)F-FDG PET/CT for detecting nodal metastases in patients with muscle-invasive urothelial bladder cancer prior to radical cystectomy. MATERIALS AND METHODS: Preoperative (18)F-FDG PET/CT scans (n = 208) were retrospectively reviewed. Scans were routinely performed in 185 patients with muscle-invasive urothelial bladder cancer between August 2012 and February 2017, all of whom underwent radical cystectomy and pelvic lymph node dissection. Anal...
Source
#1Deaglan J. McHugh (Cornell University)
#2Samuel A. Funt (Cornell University)H-Index: 2
Last. Brett S. Carver (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 40
view all 14 authors...
PURPOSEThe relapse rate after primary retroperitoneal lymph node dissection (RPLND) for patients with pathologic stage (PS) IIA nonseminomatous germ cell tumors (NSGCTs) is 10%-20% but increases to...
Source
#1Darren R. Feldman (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 30
#2Andrea Knezevic (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 8
Last. Emily S. Tonorezos (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 13
view all 12 authors...
Source
#1Timothy Nguyen Clinton (MSK: Memorial Sloan Kettering Cancer Center)
#2Hannah C. Wise (MSK: Memorial Sloan Kettering Cancer Center)
Last. Maria I. Carlo (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 9
view all 20 authors...
529Background: Large-scale efforts have sought to define the genomic landscape of urothelial carcinomas of the bladder with the goal of identifying novel therapeutic targets. Many bladder cancers h...
Source
#1Michal Sarfaty (MSK: Memorial Sloan Kettering Cancer Center)
#2Irina Ostrovnaya (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 27
Last. Grace Hettich (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
view all 15 authors...
514Background: Non-transitional cell carcinoma of the urothelial tract (non-TCC) includes several distinct histologies and is associated with a poor prognosis. Prospective data regarding management...
Source
#1Yung Lyou (City of Hope National Medical Center)
#2Petros Grivas (UW: University of Washington)H-Index: 19
Last. Sumati Gupta (HCI: Huntsman Cancer Institute)H-Index: 8
view all 18 authors...
576Background: Infigratinib (BGJ398) is a potent and selective FGFR1–3 inhibitor with significant clinical activity in aUC bearing FGFR3 alterations. A common adverse event is hyperphosphatemia, a ...
Source
#1Nathan Colin Wong (MSK: Memorial Sloan Kettering Cancer Center)
#2Soleen Ghafoor (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 5
Last. Jonathan A. Coleman (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 37
view all 5 authors...
522Background: Neoadjuvant chemotherapy (NAC) has established survival benefits prior to radical cystectomy for bladder cancer, yet its role in upper tract urothelial carcinoma (UTUC) prior to neph...
Source
#1Eugene K. Cha (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 29
#2Gopa Iyer (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 26
Last. Bernard H. Bochner (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 55
view all 11 authors...
Source
#1Nathan Colin Wong (MSK: Memorial Sloan Kettering Cancer Center)
#2Melissa Assel (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 12
Last. Dean F. Bajorin (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 65
view all 11 authors...
Source
12345678910